FDA grants Orphan Drug Designation to Faron’s bexmarilimab in AML
The ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme
Read More
Tag: acute myeloid leukaemia
EMA accepts application for leukaemia drug from Otsuka and Astex
The marketing authorisation application is supported by results from a phase 3 trial for AML
Read More
Researchers identify new genetic target for acute myeloid leukaemia
Targeting a specific mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients
Read More
ICR’s ‘resistance-busting’ drug advances into Phase I trial
EP0042 is a dual-inhibitor drug designed to block the activity of two cancer-driving proteins
Read More
BMS bags US approval for Onureg
The oral therapy can be used as continued treatment for adults in first remission with acute myeloid leukaemia (AML)
Read More
NICE publishes guidance on Astellas’ Xospata
The final green light backs NHS use of the drug
Read More
Venclexta/Venclyxto combo extends myeloid leukaemia survival
Roche also reported that safety for Venclexta/Venclyxto with azacitidine appeared consistent with the known safety profile of these medicines.
Read More
Final NICE green light for Pfizer’s Mylotarg
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
Pfizer’s Mylotarg wins EU approval for AML
European regulators have cleared Pfizer’s Mylotarg to treat a certain subset of patients with acute myeloid leukaemia (AML).
Read More
Pfizer’s Mylotarg returns to market after seven-year hiatus
US regulators have issued a green light for Pfizer’s Mylotarg as a treatment for acute myeloid leukaemia (AML), seven years after the drug was with voluntarily withdrawn from the market.
Read More
Green light for Celgene’s targeted AML drug
US regulators have issued a green light for Celgene and Agios’ Idhifa, the first and only targeted treatment for adult patients with relapsed/refractory acute myeloid leukaemia and an isocitrate dehydrogenase-2 mutation.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
